Orchestra BioMed Holdings Inc (OBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.08+7.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -27.3% |
| Our one-year growth estimate | diamond | -95.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 67.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OBIO — officer change
Dated 2026-02-13
The filing describes the approval of a new cash bonus plan and updated RSU vesting policy, which are routine management actions.
Why it matters: PPI affects prices in health care. This can change how much money companies make.
Watch forPPI shows a big increase. This means companies have stronger pricing power.
Also watch forPPI shows a big decrease. This means companies have weaker pricing power.
Why it matters: If revenue growth speeds up, it could be good for Orchestra BioMed.
Supportive ifRevenue growth in the health care sector re-accelerates back toward its highs, above 9%.
Worry ifRevenue growth is slowing down and is now below 9%.
Why it matters: The earnings report will share updates on how the company is doing financially. It will also show the company's plans for the future.
Watch forAnnouncement of the next earnings date with positive guidance on revenue growth.
Also watch forNo announcement of the earnings date or negative guidance on revenue growth.
Why it matters: If revenue growth falls below median, it signals a slowdown in the healthcare sector. This could hurt the stock.
Worry ifRevenue growth reported below the sector median of 24%.
Less concerning ifRevenue growth remains above the sector median of 24%.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$190 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $564 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,477 loss on $10,000 · 34.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.